Modelling therapy resistance in BRCA1/2 mutant cancers

Although PARP inhibitors target BRCA1 or BRCA2 mutant tumour cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or “revertant” mutations in BRCA1 or BRCA2. Whether secondary mutant tumour cells are selected for in a Darwinian fashion...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Dréan, Amy, Williamson, Chris T., Brough, Rachel, Brandsma, Inger, Menon, Malini, Konde, Asha, Garcia-Murillas, Isaac, Pemberton, Helen N., Frankum, Jessica, Rafiq, Rumana, Badham, Nick, Campbell, James, Gulati, Aditi, Turner, Nicholas C., Pettitt, Stephen J., Ashworth, Alan, Lord, Christopher J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6157714/
https://ncbi.nlm.nih.gov/pubmed/28619759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados